ТОО "VELCORA CLINIC"
This is a company preview
Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.
Risks
0/18Комитет государственных доходов · Государственные закупки РК · АО ФНБ «Самрук-Казына» · АОО «НИШ»Комитет государственных доходов · data up to 14.01.2026
This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.
Procurement signals
Court cases
Arrests & encumbrances
Enforcement proceedings
Certificates
Licenses and permits
Summary
Министерство юстиции РКActivities
86210 Общая врачебная практика
Общая врачебная практика
Contacts
Change history
Financial statements
PremiumPublic contracts
What it sells and where
Samruk-Kazyna procurement
Tender bids
Procurement as a customer
Assets
Bank accounts
Leadership
3- МД
Мейрамбекұлы Диас
Director
Former directors
- ДАДОЛАНБАЕВ АЗАМАТ ОМИРСЕРИКҰЛЫ
- ДАДОЛАНБАЕВА АСИЛХАН ТОЛОНОВНА
Founders
Accreditations
Employees
Affiliated companies
PremiumDirector's involvement in other legal entities
Branches
Company networks
PremiumSimilar companies
Media mentions
Company summary
Active legal entity ТОО "VELCORA CLINIC" (BIN 130840005164), Almaty. Registered in 2013, 13 years on the market. Main activity: healthcare. Small enterprise, headcount: up to 5 employees. Automated screening of open registries found no risk indicators for «VELCORA CLINIC». Date of the last change record: June 1, 2026 (change of address). Number of founders: 2. Director on record: Мейрамбекұлы Диас. Per the registry as of June 11, 2026.
Data sources and disclaimer
Sources: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is collected automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the fact. This is reference information and does not replace an official extract. Methodology: SafeDeal editorial policy.